Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed August 2026
Key Takeaways
- No single finding is diagnostic; suspicion depends on a cluster of cardiac and extracardiac clues, and coexisting disease can obscure the pattern.
- Excluding AL amyloidosis is central because it mimics ATTR-CM and follows a different, often more urgent pathway; serum free light chains with serum and urine immunofixation electrophoresis are the key screen.
- Echocardiography, cardiac MRI, and 99mTc-PYP scintigraphy refine probability, but each requires clinical context and AL exclusion to interpret.
- N-terminal pro-B-type natriuretic peptide (NT-proBNP) and troponin reflect myocardial stress or injury rather than amyloid type; a pathogenic transthyretin (TTR) variant confirms hereditary disease, but a negative result doesn't exclude wild-type ATTR-CM.
When to Escalate to a Structured Amyloidosis Workup
The move from routine cardiomyopathy evaluation to a structured amyloidosis workup should be driven by a pattern, not by any one finding. The presenting phenotype is often nonspecific and overlaps with hypertensive heart disease, hypertrophic cardiomyopathy, aortic stenosis, heart failure with preserved ejection fraction (HFpEF), and ischemic disease. Suspicion usually rises from a cluster: ventricular wall thickening out of proportion to electrocardiogram (ECG) voltage, diastolic or restrictive filling, atrial arrhythmias, conduction disease, heart failure symptoms disproportionate to coronary or valvular findings, and extracardiac clues such as bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture, peripheral neuropathy, or autonomic features. Each makes ATTR-CM more plausible, but none is individually diagnostic and coexisting cardiac disease can blur the picture. Deciding at what point clinical suspicion is high enough to justify starting a formal amyloidosis workup is the central challenge in early detection.
Excluding AL Amyloidosis First
AL amyloidosis must be excluded early because it can closely mimic ATTR-CM clinically and on imaging, yet it requires a different and often more urgent treatment pathway. Serum free light chain testing together with serum and urine immunofixation electrophoresis helps identify or exclude a monoclonal protein that would redirect the workup toward a plasma cell dyscrasia. A negative screen meaningfully narrows the differential but doesn't by itself establish ATTR-CM; conversely, a positive monoclonal result doesn't automatically exclude ATTR-CM because incidental monoclonal gammopathy is common in older adults and mixed disease is possible.
What Echocardiography and Cardiac MRI Can and Cannot Show
Echocardiography and cardiac MRI refine the probability of infiltrative disease rather than confirming amyloid type. Echocardiography can raise suspicion when wall thickening is accompanied by restrictive filling, biatrial enlargement, valvular or right-sided involvement, or a strain pattern compatible with amyloid, but overlap with hypertensive remodeling, hypertrophic cardiomyopathy, and aortic stenosis remains substantial. Cardiac MRI can strengthen suspicion through diffuse late gadolinium enhancement and abnormal tissue characterization, yet it can't determine whether amyloid is the ATTR or AL type on its own. Both are inputs to the overall diagnostic assessment, not endpoints in themselves.
How Much 99mTc-PYP Scintigraphy Settles
A typical 99mTc-PYP scintigraphy pattern can strongly support ATTR-CM, but only when AL amyloidosis has been excluded and the broader workup is concordant. Grade 2-3 myocardial uptake with a supportive heart-to-contralateral ratio in a patient without a monoclonal protein carries high diagnostic value for ATTR-CM. The caveats matter, though, as AL amyloidosis can also show myocardial uptake, planar imaging alone can be misleading without single-photon emission computed tomography (SPECT) to confirm myocardial rather than blood-pool signal, and indeterminate or mixed-disease scenarios still require caution. PYP is a powerful step in the sequence, not a substitute for the sequence.
The Limited Role of Biomarkers and Genetic Testing
Neither resolves the diagnosis on its own. NT-proBNP and troponin are best read as contextual markers of myocardial stress or injury, not as discriminators between ATTR-CM and its mimics; chronic kidney disease, atrial arrhythmias, aortic stenosis, and ischemic disease can all produce similar elevations. Genetic testing adds a different layer once transthyretin amyloidosis is established. A pathogenic TTR variant identifies hereditary ATTR-CM and has family-screening implications, while a negative result doesn't exclude wild-type disease. A confident diagnosis therefore requires a staged synthesis of phenotype, extracardiac context, monoclonal protein assessment, imaging, and—when indicated—tissue confirmation, which is where specialized amyloidosis center experience is particularly valuable.
Practical Workup Checklist
Before attributing increased wall thickness or restrictive physiology to a common cause, confirm:
- Do cardiac and extracardiac clues cluster (wall thickness out of proportion to voltage, conduction disease, carpal tunnel, neuropathy)?
- Have serum free light chains plus serum and urine immunofixation electrophoresis been done to screen for AL amyloidosis?
- Was 99mTc-PYP scintigraphy interpreted with SPECT and only after AL exclusion?
- Has TTR genetic testing been arranged once transthyretin amyloidosis is established to separate hereditary from wild-type disease?
- Is referral to an amyloidosis center warranted when the pattern is uncertain, discordant, or suggests mixed disease?
Clinical Decision Point
A confident ATTR-CM diagnosis depends on the order and concordance of the workup, not on the single most impressive test. The decision is whether AL amyloidosis has been adequately excluded and whether imaging, biomarkers, and phenotype point the same way; when findings are discordant, the appropriate response is to continue the evaluation or refer to a specialist rather than act on a single result. A secure, fully classified diagnosis is required before initiating disease-directed therapy.
Frequently Asked Questions
When should I move from a routine cardiomyopathy workup to an amyloidosis workup?
Move to an amyloidosis workup when the overall pattern—not a single finding—raises suspicion: wall thickening out of proportion to ECG voltage, restrictive filling, atrial arrhythmias, conduction disease, heart failure symptoms disproportionate to coronary or valvular disease, and extracardiac clues such as carpal tunnel syndrome, spinal stenosis, biceps tendon rupture, neuropathy, or autonomic features.
Which tests are most important for separating ATTR-CM from AL amyloidosis?
The key tests are serum free light chain testing together with serum and urine immunofixation electrophoresis. A negative screen narrows the differential but doesn't establish ATTR-CM, and a positive monoclonal result doesn't automatically exclude it, especially in older patients where incidental monoclonal gammopathy or mixed disease can occur.
Can 99mTc-PYP scintigraphy alone confirm ATTR-CM?
No. A typical PYP pattern can strongly support ATTR-CM when AL amyloidosis has been excluded and the rest of the workup agrees, but it should be interpreted with SPECT and in clinical context. False-positive, indeterminate, and mixed-disease scenarios require caution.
Do NT-proBNP and troponin help identify the amyloid type?
No. They reflect myocardial stress or injury and are useful for staging and follow-up, but they don't distinguish ATTR-CM from its mimics, and several non-amyloid conditions can raise them.
If genetic testing is negative, is ATTR-CM ruled out?
No. A pathogenic TTR variant confirms hereditary ATTR-CM, but a negative result doesn't exclude wild-type ATTR-CM, which is the more common form in older adults.
Related Reading
Part of the Spotlight On ATTR-CM resource center.
Build the Workup
- Screening and Early Detection in ATTR-CM
- Diagnostic Criteria in ATTR-CM
- Excluding AL and Reading the Phenotype
Then Treat
See the Guidance
References:
- World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart
- Best Practices in Specialized Amyloidosis Centers in the United States. Clinical Medicine Insights: Cardiology
- Transthyretin Amyloid Cardiomyopathy—2025 Update: Current Diagnostic Approaches and Emerging Therapeutic Options. Journal of Clinical Medicine
- Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association. Circulation
This content is intended for healthcare professionals for educational purposes and isn't a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.